Why the study?
Does pirbuterol improve symptoms, haemodynamics, and exercise capacity in patients with severe chronic heart failure?
Population
63 patients with severe chronic heart failure (NYHA class III and IV)
Design
Cohort, open-label
Follow-up
3 months
Authors
Loading...
High mortality without symptomatic or exercise gains despite sustained haemodynamics advises caution in severe HF; leaves open efficacy in randomized trials.
Does pirbuterol improve symptoms, haemodynamics, and exercise capacity in patients with severe chronic heart failure?
Pirbuterol provides sustained haemodynamic improvement in severe heart failure, but this does not translate to symptomatic benefit and is associated with high mortality.
Dawson et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: